Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Dec 6;18(1):204.
doi: 10.1186/s12931-017-0686-7.

Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study

Affiliations
Multicenter Study

Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study

Sang Hoon Lee et al. Respir Res. .

Abstract

Background: The effects of corticosteroid-based therapy in patients with idiopathic nonspecific interstitial pneumonia (iNSIP), and factors affecting treatment outcome, are not fully understood. We aimed to investigate the long-term treatment response and factors affecting the treatment outcome in iNSIP patients from a multi-center study in Korea.

Methods: The Korean interstitial lung disease (ILD) Study Group surveyed ILD patients from 2003 to 2007. Patients were divided into two groups to compare the treatment response: response group (forced vital capacity (FVC) improves ≥10% after 1 year) and non-response group (FVC <10%). Factors affecting treatment response were evaluated by multivariate logistic regression analysis.

Results: A total of 261 patients with iNSIP were enrolled, and 95 patients were followed-up for more than 1 year. Corticosteroid treatment was performed in 86 patients. The treatment group showed a significant improvement in lung function after 1-year: FVC, 10.0%; forced expiratory volume (FEV1), 9.8%; diffusing capacity of the lung for carbon monoxide (DLco), 8.4% (p < 0.001). Sero-negative anti-nuclear antibody (ANA) was significantly related with lung function improvement. Sero-positivity ANA was significantly lower in the response group (p = 0.013), compared to that in the non-response group. A shorter duration of respiratory symptoms at diagnosis was significantly associated with a good response to treatment (p = 0.018).

Conclusion: Treatment with corticosteroids and/or immunosuppressants improved lung function in iNSIP patients, which was more pronounced in sero-negative ANA and shorter symptom duration patients. These findings suggest that early treatment should be considered in iNSIP patients, even in an early disease stage.

Keywords: Non-specific interstitial pneumonia; Pulmonary lung function; Treatment.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The Institutional Review Board (IRB) of Yonsei University Health Service, Severance Hospital, reviewed and approved the study protocol (Reference number for ethics approval: 4–2009-0372).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow chart of the study population. Initially, 2186 patients with interstitial lung disease (ILD) were enrolled by the Korean study group between January 1, 2003, and December 31, 2007. A total of 261 surgically diagnosed patients with non-specific interstitial pneumonia (NSIP) were analyzed in this study; 1925 patients with a different diagnosis other than NSIP were excluded from this study. One hundred and fifty seven patients were followed-up within 1 year, and 95 patients were followed-up after >1 year. Of these 95 patients, nine were in the conservative care group, and 86 in the treatment group. The treatment group was defined as those prescribed corticosteroid and/or immunosuppressant therapy, and conservative care group was defined as those who were only prescribed medication for symptom control. IPF: idiopathic pulmonary fibrosis, COP: cryptogenic organizing pneumonia, AIP: acute interstitial pneumonia, DIP: desquamative interstitial pneumonia, RB-ILD: respiratory bronchiolitis-associated interstitial lung disease, LIP: lymphocytic interstitial pneumonia
Fig. 2
Fig. 2
Changes in lung function over time between the response group and non-response group. a Change in functional vital capacity (FVC) (%) over time between the two groups (p < 0.001, Mean ± standard error (SE), b Change in the diffusing capacity of the lung for carbon monoxide (DLCO) (%) over time between the two groups (p = 0.002, Mean ± SE)

References

    1. Flaherty KR, Martinez FJ. Nonspecific interstitial pneumonia. Semin Respir Crit Care Med. 2006;27:652–658. doi: 10.1055/s-2006-957336. - DOI - PubMed
    1. Travis WD, Hunninghake G, King TE, Jr, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008;177:1338–1347. doi: 10.1164/rccm.200611-1685OC. - DOI - PubMed
    1. Belloli EA, Beckford R, Hadley R, Flaherty KR. Idiopathic non-specific interstitial pneumonia. Respirology. 2016;21:259–268. doi: 10.1111/resp.12674. - DOI - PubMed
    1. Kligerman SJ, Groshong S, Brown KK, Lynch DA. Nonspecific interstitial pneumonia: radiologic, clinical, and pathologic considerations. Radiographics. 2009;29:73–87. doi: 10.1148/rg.291085096. - DOI - PubMed
    1. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46:976–987. doi: 10.1183/13993003.00150-2015. - DOI - PubMed

Publication types

Substances

LinkOut - more resources